Wednesday, April 20 Scientific Platform Sessions 1:00 p.m.–3:00 p.m. Scientific Platform Sessions S39: Aging and Dementia: Pathology and Imaging 1:00 p.m. S39.001 Deep Clinical and Neuropathological Phenotyping of Pick’s Disease —David Irwin, Johannes Brettschneider, Corey McMillan, Felicia Cooper, Christopher Olm, Steven Arnold, Vivianna Van Deerlin, William Seeley, Bruce Miller, Edward Lee, Virginia Lee, Murray Grossman, John Trojanowski 1:15 p.m. S39.002 Clinicopathological Correlations of AD Neuropathology in the Logopenic Variant of Primary Progressive Aphasia —Lucia Giannini, David Irwin, Corey McMillan, Sharon Ash, David Wolk, Anna Isenberg, Katya Rascovsky, John Trojanowski, Murray Grossman 1:30 p.m. S39.003 Relationship Between Hippocampal Sclerosis and TDP-43, and Duration of the Symptoms of Dementia in Alzheimer’s Disease Patients —Oscar Lopez, Julia Kofler, Alexis Steinberg, James Becker, Robert Sweet, Sarah Berman, Eric McDade, Eric Rodriguez, Ilyas Kamboh, William Klunk 1:45 p.m. S39.004 Validity of Clinical Research Criteria for Chronic Traumatic Encephalopathy: The Understanding Neurologic Injury and Traumatic Encephalopathy (UNITE) Study —Jesse Mez, Todd Solomon, Daniel Daneshvar, Philip Montenigro, Patrick Kiernan, Lauren Murphy, Joshua Kriegel, Bobak Abdolmohamadi, Michael Alosco, Thor Stein, Lee Goldstein, Douglas Katz, Neil Kowall, Robert Cantu, Robert Stern, Ann McKee 2:00 p.m. S39.005 Plasma Neurofilament Light Chain Predicts Progression in Progressive Supranuclear Palsy —Julio Rojas -Martinez, Anna Karydas, Jee Bang, Richard Tsai, Kaj Blennow, Victor Liman, Joel Kramer, Howard Rosen, Bruce Miller, Henrik Zetterberg, Adam Boxer 2:15 p.m. S39.006 Effects of Brain Derived Neurotrophic Factor on White Matter Integrity in Middle-Aged Adults: A Voxel-Based Diffusion Tensor Imaging Study — Pauline Maillard, Claudia Satizabal, Alexa Beiser, Jayandra Himali, Tai Chen, Ramachandran Vasan, Sudha Seshadri, Charles DeCarli 2:30 p.m. S39.007 Cascading Network Failure Across the Alzheimer’s Disease Spectrum —David Jones, David Knopman, Jeffery Gunter, Jonathan Graff-Radford, Prashanthi Vemuri, Bradley Boeve, Ronald Petersen, Michael Weiner, Clifford Jack 2:45 p.m. S39.008 An MRI Atlas for Imaging and Pathologic Correlation Studies in Alzheimer’s Disease —Mekala Raman, Christopher Schwarz, Melissa Murray, Val Lowe, Dennis Dickson, Clifford Jack, Kejal Kantarci S40: Movement Disorders: Parkinson's Disease Clinical Trials and Therapeutics 1:00 p.m. S40.001 RTMS for On-Freezers with Advanced PD. A Long Term Follow Up Study — Hatem Shehata, Nevin Shalaby, Mohamed El-Tamawy, Shaimaa Jaafary 1:15 p.m. S40.002 Continuous Subcutaneous Administration of Carbidopa Enhances Levodopa Pharmacokinetics: A Series of Studies Conducted in the Pig, Mouse and Healthy Volunteers —Oron Yacoby- Zeevi, Eduardo Zawoznik, Irena Weinstock, Mara Nemas, Yossi Caraco, Peter LeWitt, Sheila Oren, Ronit Shaltiel-Karyo 1:30 p.m. S40.003 Clinical Outcomes in Parkinson’s Disease for Asleep Deep Brain Stimulation with Electrodes Placed Using Intraoperative Imaging Versus Awake Deep Brain Stimulation with Microelectrode Recording —Matthew Brodsky, Shannon Anderson, Mara Seier, Jennifer Wilhelm, Kitty Leelaamornvichet, Aaron Vederman, Kim Burchiel 1:45 p.m. S40.004 EPI-743 Improves Motor Function and CNS Biomarkers in PD: Results from a Phase 2A Pilot Trial —Theresa Zesiewicz, Kevin Allison, Israt Jahan, Jessica Shaw, F. Murtagh, Tracy Jones, Clifton Gooch, Jason Salemi, Matthew Klein, Guy Miller, Kelly Sullivan 2:00 p.m. S40.005 Nilotinib Improves Motor Skills, Cognition and Autonomic Function in Open-Label Phase I Clinical Trial in Parkinsons Disease with Dementia and Lewy Body Dementia —Fernando Pagan, Ellen Valadez, Yasar Torres-Yaghi, Michaeline Hebron, Ramsey Falconer, Sean Rogers, Reversa Mills, Howard Helen, Barbara Wilmarth, Charbel Moussa 2:15 p.m. S40.006 Nilotinib Significantly Alters CSF Biomarkers and Increases Endogenous Dopamine in Open-Label Phase I Clinical Trial in Parkinsons Disease with Dementia and Lewy Body Dementia — Charbel Moussa, Michaeline Hebron, Xhaoxia Li, Huang Xu, Ellen Valadez, Torres- Yaghi Yasar, Sean Rogers, Drew Falconer, Reversa Mills, Fernando Pagan 2:30 p.m. S40.007 A Double Blind Investigation of Efficacy and Safety of IncobotulinumtoxinA in Parkinson Disease Tremor- A Customized Injection Approach — Shivam Mittal, Rezvan Rostami, Duarte Machado, Diana Richardson, Bahman Jabbari 2:45 p.m. S40.008 Computerized Alerts Can Decrease Ordering of Dopamine Blocking Drugs for Hospitalized Patients with Parkinson’s Disease —Scott Kraft S41: Advanced Neuroimaging in Multiple Sclerosis 1:00 p.m. S41.001 Structural Disconnection Is Responsible for Increased Resting State Functional Connectivity in Multiple Sclerosis — Kevin Patel, Sean Tobyne, Boratyn Daria, John Bireley, Victoria Smith, Eric Klawiter 1:15 p.m. S41.002 An Abnormal Periventricular Gradient in Magnetisation Transfer Ratio Occurs Early in Multiple Sclerosis —J William Brown, Matteo Pardini, Wallace Brownlee, Kryshani Fernando, Rebecca Samson, Claudia Nandini Wheeler-Kingshott, Olga Ciccarelli, David Miller, Declan Chard 1:30 p.m. S41.003 Neurite Orientation Dispersion and Density Imaging (NODDI) Is Sensitive to Microstructural Damage Related to Disability in Relapse-Onset MS — Wallace Brownlee, Patricia Alves Da Mota, Ferran Prados, Torben Schneider, M. George Cardoso, Daniel Altmann, Sebastien Ourselin, Claudia Gandini Wheeler-Kingshott, Olga Ciccarelli, David Miller 1:45 p.m. S41.004 Leptomeningeal Enhancement on 7T MRI in Multiple Sclerosis Is Associated with Cortical Gray Matter Atrophy — Daniel Harrison, Kevin Wang, Fiol Julie, Walter Royal, Izlem Izbudak 2:00 p.m. S41.005 Cortical [11C]PBR28 PET Measures of Microglial Inflammation Explain Differences in Cognitive Performance of People with MS —Gourab Datta, Marco Battaglini, Gregory Scott, Özgür Yaldizli, Andre Santos-Ribeiro, Eugenii Rabiner, Roger Gunn, David Owen, Omar Malik, Olga Ciccarelli, Richard Nicholas, Dawn Langdon, Nicola De Stefano, Paul Matthews 2:15 p.m. S41.006 Leptomeningeal Contrast Enhancement is Associated with Development of Gray Matter Atrophy Over 5 Years in Multiple Sclerosis —Robert Zivadinov, Deepa Ramasamy, Sirin Gandhi, Avinash Chandra, Jesper Hagemeier, Niels Bergsland, David Hojnacki, Bianca Weinstock-Guttman 2:30 p.m. S41.007 Brain Tissue Sodium Concentration in Clinically Isolated Syndrome —Niamh Cawley, Bhavana Solanky, Ferran Prados, Sara Collorone, Sebastian Ourselin, Claudia Gandini Wheeler-Kingshott, Ahmed Toosy, David Miller, Alan Thompson, Olga Ciccarelli 2:45 p.m. S41.008 Differential Relationship Between Cortical Thinning and Myelin Water Fraction in RRMS and SPMS —Michael Dayan, Sandra Hurtado Rua, Elizabeth Monohan, Sneha Pandya, Jai Perumal, Nancy Nealon, Timothy Vartanian, Thanh Nguyen, Ashish Raj, Susan Gauthier $ A registration fee is required L The program is one of the AAN Leadership University sessions S The course is part of a Subspecialty in Focus track I The program is one of the I Talk sessions Learning Lab Excitement of Discovery Health & Wellness Real World of Neurology The program is part of the Experiential Learning Area sessions 124 2016 AAN Annual Meeting Abstract Listing
Meeting Schedule 1:00 p.m.–3:00 p.m. S39 Aging and Dementia: Pathology and Imaging S40 Movement Disorders: Parkinson’s Disease Clinical Trials and Therapeutics S41 Advanced Neuroimaging in Multiple Sclerosis Real World of NeurologyAsk the Expert: Telemedicine Director: Eric Anderson, MD, PhD, Decatur, GA C177 Therapy in Neurology III Director: Steven L. Lewis, MD, FAAN, Chicago, IL C178 Clinical Epilepsy II Director: Page B. Pennell, MD, Boston, MA C179 Sports Concussion and Other Mild Concussive Injuries I Director: David W. Dodick, MD, Phoenix, AZ C180 Genomic Neurology Workshop: Developing Practical Knowledge of Tools and Concepts Through Case Studies I (registration required) Director: Jeffery M. Vance, MD, PhD, Miami, FL C181 Multiple Sclerosis Therapy: Disease-modifying Treatment I Director: Bruce A. C. Cree, MD, PhD, MCR, San Francisco, CA C182 Neuro-otology I Director: Terry D. Fife, MD, FAAN, Phoenix, AZ C183 Clinical EMG II Director: Mark B. Bromberg, MD, PhD, FAAN, Salt Lake City, UT C184 Navigating Primary Brain Tumors for the Neurologist I Director: Erin M. Dunbar, MD, Atlanta, GA C185 Autism Spectrum Disorders - What We Know and Where We Are Going Director: Patricia K. Crumrine, MD, FAAN, Pittsburgh, PA C186 Neurologic Case Studies in Pregnancy I Director: Mary Angela O’Neal, MD, Boston, MA C187 Rehabilitation in Neurology Director: Karunesh Ganguly, MD, PhD, San Francisco, CA C188 $ Clinical Uses of Botulinum Toxin for Headache Skills Workshop (registration required) Director: Andrew M. Blumenfeld, MD, Encinitas, CA 1:00 p.m.–5:00 p.m. C234 L $ The Most Important Tool in Your Black Bag: Gallup StrengthsFinder Assessment II (registration required) Directors: Julie Anderson, Stillwater, MN Keri Bischoff, Stillwater, MN Health & Wellness Friday, April 15–Thursday, April 21: 7:00 a.m.–5:30 p.m. Location: West Level 1 Health & Wellness: Taking Care of Yourself So That You Can Take Care of Others! Get educated, inspired, and motivate about the importance of taking care of your mental and physical health at this exciting new Experiential Learning Area at the 2016 AAN Annual Meeting. Learn about the importance of interventions, such as exercise and nutrition, for personal well-being and as part of a treatment program for your patients. Recharge with a healthy beverage, receive a free chair massage, participate in fun and functional mental and physical fitness breaks—including yoga and guided meditation sessions—or in lively group discussions, or join the AAN Annual Meeting Step Challenge for a chance to win daily prizes. Learn more at AAN.com/view/HealthWellness. Wed· April 20 Fast and easy registration · AAN.com/view/AM16 125
Change language